Featured Content
H. Jack West, MD
Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)
New Treatment Combination Benefited Patients With Lung Cancer
(AACR) July 29, 2014 - A combination of the EGFR-targeted anticancer therapeutics afatinib (Gilotrif) and cetuximab (Erbitux) yielded clinical responses in 29 percent of patients who had lung cancer harbouring epidermal growth factor receptor (EGFR) mutations that had stopped responding to the EGFR inhibitors erlotinib (Tarceva) and gefitinb (Iressa), according to data from a phase Ib clinical trial.
Commentary: While this work is promising, it's no longer very new, having been presented at major medical meetings more than...
 |
Our free daily oncology focused e-news service.
Subscribe» | Search Archives» |
Today's News
ALTTO Fallout Focuses Debate on the Meaning of pCR
(Medscape Medical News) July 29, 2014 - This summer, results from the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial sparked a controversy that is gathering momentum.
read article (free registration required) »
Stivarga (regorafenib) from Bayer Approved in the European Union for the Treatment of Gastrointestinal Stromal Tumors
(Bayer) July 30, 2014 – The oncology compound Stivarga® (regorafenib) from Bayer has been approved by the European Commission (EC) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.
read corporate press release »
Getting Hospice Care Shouldn't Have To Mean Giving Up
(NPR Shots blog/Kaiser Health News) July 29, 2014 - It's a painful dilemma for seriously ill Medicare patients: To receive the extra support, counseling and care provided by the program's hospice benefit, they have to agree to stop receiving curative treatment for their disease.
read article »
News Story Commentary By Academic and Community Oncologists
|
Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape. OBR Job BoardSunesis Pharmaceuticals, Inc. has 2 jobs posted. Novocure has posted 4 jobs. |
The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™
View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.
View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results
Date: mid-2014
Company: Threshold Pharmaceuticals / Merck KGaA
Product: TH-302
Date: August 9, 2014
Company: Spectrum Pharmaceuticals / Topotarget
Product: Beleodaq™ (belinostat) for Injection
Date: Q3 2014
Company: Amgen
Product: Kyprolis® (carfilzomib)
OBR's Oncology Events Calendar is a compilation of important upcoming conferences and meetings that is updated daily.
Through Aug 9
Through Aug 13
Through Aug 16
Through Aug 23